GlassScriptPhysician profile
Paul Kuperschmid
NPI 1861463754
$7,353.33
in general payments reported to CMS, 2019-2025
27 companies · $341 in 2025
The $341 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,013 · 2020: $1,249 · 2021: $1,508 · 2022: $103 · 2023: $1,124 · 2024: $14.61 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,329 · Education: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,329.04 |
| Education | $150.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,237.47 | 2019-2024 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $861.45 | 2019-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $753.88 | 2019-2025 | Ofev |
| Mylan Specialty L.P. | $579.44 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $384.19 | 2019-2025 | Opsumit, Uptravi |
| Philips North America LLC | $365.07 | 2019-2022 | |
| Pulmonx Corporation | $274.53 | 2019-2023 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Genzyme Corporation | $252.54 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $231.83 | 2019-2020 | |
| Grifols USA, LLC | $194.45 | 2019-2021 | |
| Genentech USA, INC. | $192.15 | 2019-2020 | |
| Amgen INC. | $174.96 | 2022-2023 | Tezspire |
| Advanced Respiratory, INC | $158.61 | 2019-2021 | |
| Shire North American Group INC | $116.94 | 2019 | |
| Novartis Pharmaceuticals Corporation | $105.90 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $101.75 | 2019-2021 | |
| Circassia INC. | $64.36 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $56.50 | 2019 | |
| Electromed, INC. | $44.50 | 2021 | |
| Pfizer INC. | $40.47 | 2019 | |
| Mallinckrodt Hospital Products INC. | $32.22 | 2021 | |
| Insmed, INC. | $31.94 | 2021 | |
| Covis Pharma Gmbh | $25.72 | 2020 | |
| Gilead Sciences, INC. | $20.61 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.51 | 2020 | |
| Jazz Pharmaceuticals INC. | $18.54 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Kuperschmid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.